| Gene symbol | STAT3 | Synonyms | ADMIO, ADMIO1, APRF, HIES | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q21.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | signal transducer and activator of transcription 3 | ||||
| GTO ID | GTC3404 |
| Trial ID | NCT05814666 |
| Disease | Head and Neck Squamous Cell Carcinoma |
| Altered gene | STAT3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS-STAT3rx|AZD9150|ISIS 481464|IONIS-STAT3-2.5Rx |
| Co-treatment | pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Year | 2023 |
| Country | United States|Korea, Republic of |
| Company sponsor | Flamingo Therapeutics NV |
| Other ID(s) | FLM-6774-201 |
| Vector information | |||
|
|||
| Cohort1: Danvatirsen_pembrolizumab | |||||||
|
|||||||
| Cohort2: pembrolizumab | |||||||
|
|||||||